Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

The Evolving Modern Management of Brain Metastasis.

Fecci PE, Champion CD, Hoj J, McKernan C, Goodwin CR, Kirkpatrick J, Anders CK, Pendergast AM, Sampson JH.

Clin Cancer Res. 2019 Jun 18. pii: clincanres.1624.2019. doi: 10.1158/1078-0432.CCR-18-1624. [Epub ahead of print]

PMID:
31213459
2.

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.

Henry NL, Somerfield MR, Abramson VG, Ismaila N, Allison KH, Anders CK, Chingos DT, Eisen A, Ferrari BL, Openshaw TH, Spears PA, Vikas P, Stearns V.

J Clin Oncol. 2019 Jun 17:JCO1900948. doi: 10.1200/JCO.19.00948. [Epub ahead of print]

PMID:
31206315
3.

Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.

Nyrop KA, Deal AM, Reeder-Hayes KE, Shachar SS, Reeve BB, Basch E, Choi SK, Lee JT, Wood WA, Anders CK, Carey LA, Dees EC, Jolly TA, Kimmick GG, Karuturi MS, Reinbolt RE, Speca JC, Muss HB.

Cancer. 2019 May 15. doi: 10.1002/cncr.32175. [Epub ahead of print]

PMID:
31090930
4.

ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.

Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Dieras V, Müller V, Tagliaferri M, Hannah AL, Cortés J.

Future Oncol. 2019 May 10. doi: 10.2217/fon-2019-0180. [Epub ahead of print]

5.

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O'Sullivan CC, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU; Translational Breast Cancer Research Consortium.

J Clin Oncol. 2019 May 1;37(13):1081-1089. doi: 10.1200/JCO.18.01511. Epub 2019 Mar 12.

PMID:
30860945
6.

Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer.

Nyrop KA, Deal AM, Shachar SS, Basch E, Reeve BB, Choi SK, Lee JT, Wood WA, Anders CK, Carey LA, Dees EC, Jolly TA, Reeder-Hayes KE, Kimmick GG, Karuturi MS, Reinbolt RE, Speca JC, Muss HB.

Oncologist. 2019 Jun;24(6):762-771. doi: 10.1634/theoncologist.2018-0590. Epub 2018 Dec 14.

PMID:
30552158
7.

Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ.

Kumar S, Lindsay D, Chen QB, Garrett AL, Tan XM, Anders CK, Carey LA, Gupta GP.

NPJ Breast Cancer. 2018 Dec 5;4:39. doi: 10.1038/s41523-018-0093-3. eCollection 2018.

8.

Dual HER2-Targeting in the Adjuvant Setting: Where We Have Been and Where We Are Going.

Copeland AC, Anders CK.

Oncology (Williston Park). 2018 Oct 15;32(10):483-7. Review.

9.

Breast cancer in adolescents and young adults.

Johnson RH, Anders CK, Litton JK, Ruddy KJ, Bleyer A.

Pediatr Blood Cancer. 2018 Dec;65(12):e27397. doi: 10.1002/pbc.27397. Epub 2018 Aug 28. Review.

PMID:
30156052
10.

LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.

Van Swearingen AED, Siegel MB, Deal AM, Sambade MJ, Hoyle A, Hayes DN, Jo H, Little P, Dees EC, Muss H, Jolly T, Zagar TM, Patel N, Miller CR, Parker JS, Smith JK, Fisher J, Shah N, Nabell L, Nanda R, Dillon P, Abramson V, Carey LA, Anders CK.

Breast Cancer Res Treat. 2018 Oct;171(3):637-648. doi: 10.1007/s10549-018-4852-5. Epub 2018 Jun 25.

PMID:
29938395
11.

Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies.

Brosnan EM, Anders CK.

Ann Transl Med. 2018 May;6(9):163. doi: 10.21037/atm.2018.04.35. Review.

12.

Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer.

Siegel MB, He X, Hoadley KA, Hoyle A, Pearce JB, Garrett AL, Kumar S, Moylan VJ, Brady CM, Van Swearingen AE, Marron D, Gupta GP, Thorne LB, Kieran N, Livasy C, Mardis ER, Parker JS, Chen M, Anders CK, Carey LA, Perou CM.

J Clin Invest. 2018 Apr 2;128(4):1371-1383. doi: 10.1172/JCI96153. Epub 2018 Feb 26.

13.

Live birth outcomes after adolescent and young adult breast cancer.

Anderson C, Engel SM, Anders CK, Nichols HB.

Int J Cancer. 2018 May 15;142(10):1994-2002. doi: 10.1002/ijc.31227. Epub 2018 Jan 4.

14.

The incidence and predictive factors for leptomeningeal spread after stereotactic radiation for breast cancer brain metastases.

Kaidar-Person O, Deal AM, Anders CK, Ewend MG, Dees EC, Camporeale J, Ramirez J, Benbow JM, Marks LB, Zagar TM.

Breast J. 2018 May;24(3):424-425. doi: 10.1111/tbj.12919. Epub 2017 Dec 18. No abstract available.

PMID:
29251377
15.

A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.

McRee AJ, Marcom PK, Moore DT, Zamboni WC, Kornblum ZA, Hu Z, Phipps R, Anders CK, Reeder-Hayes K, Carey LA, Weck KE, Perou CM, Dees EC.

Clin Breast Cancer. 2018 Aug;18(4):289-297. doi: 10.1016/j.clbc.2017.10.014. Epub 2017 Oct 28.

PMID:
29153866
16.

Biology and Etiology of Young-Onset Breast Cancers among Premenopausal African American Women: Results from the AMBER Consortium.

Chollet-Hinton L, Olshan AF, Nichols HB, Anders CK, Lund JL, Allott EH, Bethea TN, Hong CC, Cohen SM, Khoury T, Zirpoli GR, Borges VF, Rosenberg LA, Bandera EV, Ambrosone CB, Palmer JR, Troester MA.

Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1722-1729. doi: 10.1158/1055-9965.EPI-17-0450. Epub 2017 Sep 13.

17.

TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy.

Chao YL, Anders CK.

Clin Breast Cancer. 2018 Jun;18(3):e301-e304. doi: 10.1016/j.clbc.2017.08.006. Epub 2017 Aug 19. No abstract available.

PMID:
28899623
18.

Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies.

Mounsey LA, Deal AM, Keith KC, Benbow JM, Shachar SS, Zagar T, Dees EC, Carey LA, Ewend MG, Anders CK.

Clin Breast Cancer. 2018 Feb;18(1):29-37. doi: 10.1016/j.clbc.2017.07.017. Epub 2017 Aug 9.

19.

Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer.

Taylor NA, Vick SC, Iglesia MD, Brickey WJ, Midkiff BR, McKinnon KP, Reisdorf S, Anders CK, Carey LA, Parker JS, Perou CM, Vincent BG, Serody JS.

J Clin Invest. 2017 Sep 1;127(9):3472-3483. doi: 10.1172/JCI90499. Epub 2017 Aug 21.

20.

Discerning Clinical Responses in Breast Cancer Based On Molecular Signatures.

Coleman WB, Anders CK.

Am J Pathol. 2017 Oct;187(10):2199-2207. doi: 10.1016/j.ajpath.2017.08.002. Epub 2017 Aug 16. Review.

PMID:
28822803
21.

The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.

Kodack DP, Askoxylakis V, Ferraro GB, Sheng Q, Badeaux M, Goel S, Qi X, Shankaraiah R, Cao ZA, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, Wong CSF, Kloepper J, Das R, Tam A, Tanboon J, Duda DG, Miller CR, Siegel MB, Anders CK, Sanders M, Estrada MV, Schlegel R, Arteaga CL, Brachtel E, Huang A, Fukumura D, Engelman JA, Jain RK.

Sci Transl Med. 2017 May 24;9(391). pii: eaal4682. doi: 10.1126/scitranslmed.aal4682. Erratum in: Sci Transl Med. 2019 Jan 30;11(477):.

22.

Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.

Van Swearingen AED, Sambade MJ, Siegel MB, Sud S, McNeill RS, Bevill SM, Chen X, Bash RE, Mounsey L, Golitz BT, Santos C, Deal A, Parker JS, Rashid N, Miller CR, Johnson GL, Anders CK.

Neuro Oncol. 2017 Oct 19;19(11):1481-1493. doi: 10.1093/neuonc/nox052.

23.

Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.

McNeill RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DM, Bash RE, Angus SP, Herring LE, Simon JM, Skinner KR, Limas JC, Chen X, Schmid RS, Siegel MB, Van Swearingen AED, Hadler MJ, Sulman EP, Sarkaria JN, Anders CK, Graves LM, Berens ME, Johnson GL, Miller CR.

Neuro Oncol. 2017 Oct 19;19(11):1469-1480. doi: 10.1093/neuonc/nox044.

24.

Birth Outcomes Among Adolescent and Young Adult Cancer Survivors.

Anderson C, Engel SM, Mersereau JE, Black KZ, Wood WA, Anders CK, Nichols HB.

JAMA Oncol. 2017 Aug 1;3(8):1078-1084. doi: 10.1001/jamaoncol.2017.0029.

25.

Multidisciplinary Management of Breast Cancer During Pregnancy.

Shachar SS, Gallagher K, McGuire K, Zagar TM, Faso A, Muss HB, Sweeting R, Anders CK.

Oncologist. 2017 Mar;22(3):324-334. doi: 10.1634/theoncologist.2016-0208. Epub 2017 Feb 23. Review.

26.

Multidisciplinary Management of Breast Cancer Brain Metastases.

Zagar TM, Van Swearingen AE, Kaidar-Person O, Ewend MG, Anders CK.

Oncology (Williston Park). 2016 Oct 15;30(10):923-33. Review.

27.

Endocrine therapy and urogenital outcomes among women with a breast cancer diagnosis.

Landi SN, Doll KM, Bensen JT, Hendrix L, Anders CK, Wu JM, Nichols HB.

Cancer Causes Control. 2016 Nov;27(11):1325-1332. Epub 2016 Sep 28.

28.

Management of brain metastases in breast cancer.

Anders CK.

Clin Adv Hematol Oncol. 2016 Sep;14(9):686-8. No abstract available.

PMID:
27673287
29.

Use of Susceptibility-Weighted Imaging (SWI) in the Detection of Brain Hemorrhagic Metastases from Breast Cancer and Melanoma.

Franceschi AM, Moschos SJ, Anders CK, Glaubiger S, Collichio FA, Lee CB, Castillo M, Lee YZ.

J Comput Assist Tomogr. 2016 Sep-Oct;40(5):803-5. doi: 10.1097/RCT.0000000000000420.

30.

Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina Breast Cancer Study: a case-control study.

Chollet-Hinton L, Anders CK, Tse CK, Bell MB, Yang YC, Carey LA, Olshan AF, Troester MA.

Breast Cancer Res. 2016 Aug 4;18(1):79. doi: 10.1186/s13058-016-0736-y.

31.

Whole Brain Radiotherapy for Brain Metastases: Is the Debate Over?

Kaidar-Person O, Anders CK, Zagar TM.

JAMA. 2016 Jul 26;316(4):393-5. doi: 10.1001/jama.2016.8692. No abstract available.

PMID:
27458941
32.

Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT(®) nanoparticle formulation against non-small-cell lung cancer brain metastases.

Sambade M, Deal A, Schorzman A, Luft JC, Bowerman C, Chu K, Karginova O, Swearingen AV, Zamboni W, DeSimone J, Anders CK.

Nanomedicine (Lond). 2016 Aug;11(15):1947-55. doi: 10.2217/nnm-2016-0147. Epub 2016 Jul 26.

33.

Updates in the management of brain metastases.

Arvold ND, Lee EQ, Mehta MP, Margolin K, Alexander BM, Lin NU, Anders CK, Soffietti R, Camidge DR, Vogelbaum MA, Dunn IF, Wen PY.

Neuro Oncol. 2016 Aug;18(8):1043-65. doi: 10.1093/neuonc/now127. Review.

34.

The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.

Anders CK, Abramson V, Tan T, Dent R.

Am Soc Clin Oncol Educ Book. 2016;35:34-42. doi: 10.14694/EDBK_159135. Review.

35.

ACTIVITY OF TRASTUZUMAB-EMTANSINE (TDM1) IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A CASE SERIES.

Keith KC, Lee Y, Ewend MG, Zagar TM, Anders CK.

Cancer Treat Commun. 2016;7:43-46.

36.

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations.

Henry NL, Somerfield MR, Abramson VG, Allison KH, Anders CK, Chingos DT, Hurria A, Openshaw TH, Krop IE.

J Clin Oncol. 2016 Jul 1;34(19):2303-11. doi: 10.1200/JCO.2015.65.8609. Epub 2016 Mar 21.

PMID:
27001586
37.

Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma.

Tricoli JV, Blair DG, Anders CK, Bleyer WA, Boardman LA, Khan J, Kummar S, Hayes-Lattin B, Hunger SP, Merchant M, Seibel NL, Thurin M, Willman CL.

Cancer. 2016 Apr 1;122(7):1017-28. doi: 10.1002/cncr.29871. Epub 2016 Feb 5. Review.

38.

A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience.

McKee MJ, Keith K, Deal AM, Garrett AL, Wheless AA, Green RL, Benbow JM, Dees EC, Carey LA, Ewend MG, Anders CK, Zagar TM.

Oncologist. 2016 Jan;21(1):16-20. doi: 10.1634/theoncologist.2015-0328. Epub 2015 Dec 9.

39.

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA.

J Clin Oncol. 2016 Feb 20;34(6):542-9. doi: 10.1200/JCO.2015.62.1268. Epub 2015 Nov 2.

40.

Gene expression in "young adult type" breast cancer: a retrospective analysis.

Johnson RH, Hu P, Fan C, Anders CK.

Oncotarget. 2015 May 30;6(15):13688-702.

41.

Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.

Karginova O, Siegel MB, Van Swearingen AE, Deal AM, Adamo B, Sambade MJ, Bazyar S, Nikolaishvili-Feinberg N, Bash R, O'Neal S, Sandison K, Parker JS, Santos C, Darr D, Zamboni W, Lee YZ, Miller CR, Anders CK.

Mol Cancer Ther. 2015 Apr;14(4):920-30. doi: 10.1158/1535-7163.MCT-14-0474.

42.

Race, response to chemotherapy, and outcome within clinical breast cancer subtypes.

Tichy JR, Deal AM, Anders CK, Reeder-Hayes K, Carey LA.

Breast Cancer Res Treat. 2015 Apr;150(3):667-74. doi: 10.1007/s10549-015-3350-2. Epub 2015 Mar 27.

43.

Breast cancer brain metastases: evidence for neuronal-like adaptation in a 'breast-to-brain' transition?

Van Swearingen AE, Siegel MB, Anders CK.

Breast Cancer Res. 2014 May 6;16(3):304. doi: 10.1186/bcr3651.

44.

Local iontophoretic administration of cytotoxic therapies to solid tumors.

Byrne JD, Jajja MR, O'Neill AT, Bickford LR, Keeler AW, Hyder N, Wagner K, Deal A, Little RE, Moffitt RA, Stack C, Nelson M, Brooks CR, Lee W, Luft JC, Napier ME, Darr D, Anders CK, Stack R, Tepper JE, Wang AZ, Zamboni WC, Yeh JJ, DeSimone JM.

Sci Transl Med. 2015 Feb 4;7(273):273ra14. doi: 10.1126/scitranslmed.3009951.

45.

Single-nucleotide polymorphisms in DNA bypass polymerase genes and association with breast cancer and breast cancer subtypes among African Americans and Whites.

Family L, Bensen JT, Troester MA, Wu MC, Anders CK, Olshan AF.

Breast Cancer Res Treat. 2015 Jan;149(1):181-90. doi: 10.1007/s10549-014-3203-4. Epub 2014 Nov 23.

46.

Approaches for optimal drug development and clinical trial design for breast cancer brain metastasis.

Siegel MB, Van Swearingen AE, Anders CK.

Oncology (Williston Park). 2014 Jul;28(7):579, 584-5. No abstract available.

47.

Age-specific changes in intrinsic breast cancer subtypes: a focus on older women.

Jenkins EO, Deal AM, Anders CK, Prat A, Perou CM, Carey LA, Muss HB.

Oncologist. 2014 Oct;19(10):1076-83. doi: 10.1634/theoncologist.2014-0184. Epub 2014 Aug 20.

48.

New targets for triple-negative breast cancer.

Herold CI, Anders CK.

Oncology (Williston Park). 2013 Sep;27(9):846-54. Review.

49.

αB-crystallin: a novel regulator of breast cancer metastasis to the brain.

Malin D, Strekalova E, Petrovic V, Deal AM, Al Ahmad A, Adamo B, Miller CR, Ugolkov A, Livasy C, Fritchie K, Hamilton E, Blackwell K, Geradts J, Ewend M, Carey L, Shusta EV, Anders CK, Cryns VL.

Clin Cancer Res. 2014 Jan 1;20(1):56-67. doi: 10.1158/1078-0432.CCR-13-1255. Epub 2013 Oct 16.

50.

Breast cancer in adolescents and young adults: a review with a focus on biology.

Tichy JR, Lim E, Anders CK.

J Natl Compr Canc Netw. 2013 Sep 1;11(9):1060-9. Review.

PMID:
24029122

Supplemental Content

Loading ...
Support Center